Impact of Distinct Anti-Androgen Exposures on the Plasma Metabolome in Feminizing Gender-Affirming Hormone Therapy

Rebecca Shepherd,Lachlan M Angus,Toby Mansell,Bridget Arman,Bo Won Kim,Katherine Lange,David Burgner,Jessica A Kerr,Ken Pang,Jeffrey D Zajac,Richard Saffery,Ada Cheung,Boris Novakovic

DOI: https://doi.org/10.1210/clinem/dgae226

2024-04-13

The Journal of Clinical Endocrinology & Metabolism

Abstract:Abstract Context The plasma metabolome is a functional readout of metabolic activity and is associated with phenotypes exhibiting sexual dimorphism, such as cardiovascular disease. Sex hormones are thought to play a key role in driving sexual dimorphism. Objective Gender-affirming hormone therapy (GAHT) is a cornerstone of transgender care, but longitudinal changes in the plasma metabolome with feminizing GAHT have not been described. Methods Blood samples were collected at baseline and after three and six months of GAHT from transgender women (n = 53). Participants were randomized to different anti-androgens, cyproterone acetate or spironolactone. NMR-based metabolomics was used to measure 249 metabolic biomarkers in plasma. Additionally, we used metabolic biomarker data from an unrelated cohort of children and their parents (n = 3,748) to identify sex- and age-related metabolite patterns. Results We identified 43 metabolic biomarkers altered after six months in both anti-androgen groups, most belonging to the very low- or low-density lipoprotein subclasses, with all but one showing a decrease. We observed a cyproterone acetate-specific decrease in glutamine, glycine, and alanine levels. Notably, of the metabolic biomarkers exhibiting the most abundant ‘sex- and age-related’ pattern (higher in assigned female children and lower in assigned female adults, relative to assigned males), 80% were significantly lowered after GAHT, reflecting a shift toward the adult female profile. Conclusion Our results suggest an anti-atherogenic signature in the plasma metabolome after the first six months of feminizing GAHT, with cyproterone acetate also reducing specific plasma amino acids. This study provides novel insight into the metabolic changes occurring across feminizing GAHT.

endocrinology & metabolism

What problem does this paper attempt to address?

The paper attempts to address the impact of different anti-androgen drugs on the plasma metabolome of feminizing GAHT (Gender-affirming hormone therapy) patients. Specifically, the researchers aim to:

1. **Understand the impact of different anti-androgen drugs on the plasma metabolome**: By comparing the effects of two commonly used anti-androgen drugs—cyproterone acetate and spironolactone—in feminizing GAHT, the study explores their specific impacts on plasma metabolic markers.

2. **Evaluate the long-term impact of feminizing GAHT on cardiovascular metabolic markers**: The researchers aim to understand whether changes in the plasma metabolome within the first 6 months of feminizing GAHT are associated with a reduced risk of cardiovascular disease. Particular attention is given to changes in metabolic markers such as low-density lipoprotein (LDL), very low-density lipoprotein (VLDL), and the apolipoprotein B/A1 ratio (ApoB:ApoA1).

3. **Explore the differential impact of different anti-androgen drugs on specific metabolic markers**: The researchers also aim to determine whether different anti-androgen drugs lead to significant changes in certain specific metabolic markers, such as amino acid levels.

Through these research objectives, the paper aims to provide clinicians and researchers with a deeper understanding of the impact of feminizing GAHT on metabolic health, thereby optimizing treatment plans and improving the long-term health outcomes of patients.